Parkinson's disease and enhanced inflammatory response

被引：126
|
作者：
Stojkovska, Iva [1 ]
Wagner, Brandon M. [1 ]
Morrison, Brad E. [1 ]
机构：
[1] Boise State Univ, Dept Biol Sci, Boise, ID 83725 USA
来源：
EXPERIMENTAL BIOLOGY AND MEDICINE | 2015年 / 240卷 / 11期
关键词：
Parkinson's disease; neuroinflammation; inflammation; disease models; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BLOOD-BRAIN-BARRIER; SYNUCLEIN TRANSGENIC MICE; ALPHA-SYNUCLEIN; MICROGLIAL ACTIVATION; DOPAMINERGIC-NEURONS; SUBSTANTIA-NIGRA; MITOCHONDRIAL DYSFUNCTION; INTRANIGRAL INJECTION; INTERFERON-GAMMA;
D O I：
10.1177/1535370215576313
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Parkinson's disease (PD) is the first and second most prevalent motor and neurodegenerative disease, respectively. The clinical symptoms of PD result from a loss of midbrain dopaminergic (DA) neurons. However, the molecular cause of DA neuron loss remains elusive. Mounting evidence implicates enhanced inflammatory response in the development and progression of PD pathology. This review examines current research connecting PD and inflammatory response.
引用
收藏
页码：1387 / 1395
页数：9
相关论文
共 50 条
  • [11] Divergent Effects of Metformin on an Inflammatory Model of Parkinson's Disease
    Tayara, Khadija
    Espinosa-Oliva, Ana M.
    Garcia-Dominguez, Irene
    Abdul Ismaiel, Afrah
    Boza-Serrano, Antonio
    Deierborg, Tomas
    Machado, Alberto
    Herrera, Antonio J.
    Venero, Jose L.
    de Pablos, Rocio M.
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2018, 12
  • [12] Immune-related biomarkers for Parkinson's disease
    Abdi, Ilham Y.
    Ghanem, Simona S.
    El-Agnaf, Omar M.
    NEUROBIOLOGY OF DISEASE, 2022, 170
  • [13] NEUROINFLAMMATION AND IMMUNE DYSFUNCTION IN THE PATHOGENESIS OF PARKINSON'S DISEASE
    Idova, G. V.
    Alperina, E. L.
    Zhanaeva, S. Ya.
    ZHURNAL VYSSHEI NERVNOI DEYATELNOSTI IMENI I P PAVLOVA, 2023, 73 (04) : 454 - 478
  • [14] Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson's disease
    Whitton, Peter S.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2010, 11 (07) : 788 - 794
  • [15] COX-2 in the neurodegenerative process of Parkinson's disease
    Teismann, Peter
    BIOFACTORS, 2012, 38 (06) : 395 - 397
  • [16] Lipopolysaccharide animal models of Parkinson's disease: Recent progress and relevance to clinical disease
    Deng, Isaac
    Corrigan, Frances
    Zhai, Guangxi
    Zhou, Xin-Fu
    Bobrovskaya, Larisa
    BRAIN, BEHAVIOR, & IMMUNITY - HEALTH, 2020, 4
  • [17] The Noradrenergic System in Parkinson's Disease
    Paredes-Rodriguez, Elena
    Vegas-Suarez, Sergio
    Morera-Herreras, Teresa
    De Deurwaerdere, Philippe
    Miguelez, Cristina
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [18] Modeling Parkinson's Disease in Zebrafish
    Najib, Nor H. M.
    Nies, Yong H.
    Abd Halim, Syarifah A. S.
    Yahaya, Mohamad F.
    Das, Srijit
    Lim, Wei L.
    Teoh, Seong L.
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2020, 19 (05) : 386 - 399
  • [19] Astrocytes and Therapeutics for Parkinson's Disease
    Rappold, Phillip M.
    Tieu, Kim
    NEUROTHERAPEUTICS, 2010, 7 (04) : 413 - 423
  • [20] Parkinson's disease: Genetics and beyond
    Inamdar, N. N.
    Arulmozhi, D. K.
    Tandon, A.
    Bodhankar, S. L.
    CURRENT NEUROPHARMACOLOGY, 2007, 5 (02) : 99 - 113
12345